Sun Brighter After US Import Ban Worries Recede
This article was originally published in PharmAsia News
Analysts say that the US Food and Drug Administration's warning letter to India's biggest drug-maker, Sun Pharma, has helped allay investor concerns about the possibility of major delays in making the company's Halol plant compliant with the regulator's standards.
You may also be interested in...
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.